Is retinal vasculature a biomarker in amyloid proven Alzheimer's disease?

被引:60
|
作者
den Haan, Jurre [1 ]
van de Kreeke, Jacoba A. [2 ]
van Berckel, Bart N. [3 ]
Barkhof, Frederik [3 ,4 ]
Teunissen, Charlotte E. [5 ]
Scheltens, Philip [1 ]
Verbraak, Frank D. [2 ]
Bouwman, Femke H. [1 ]
机构
[1] Vrije Univ Amsterdam, Amsterdam UMC, Alzheimer Ctr Amsterdam, Amsterdam Neurosci,Dept Neurol, Amsterdam, Netherlands
[2] Vrije Univ Amsterdam, Amsterdam UMC, Dept Ophthalmol, Amsterdam, Netherlands
[3] Vrije Univ Amsterdam, Amsterdam UMC, Amsterdam Neurosci, Dept Radiol & Nucl Med, Amsterdam, Netherlands
[4] UCL, Inst Neurol & Healthcare Engn, London, England
[5] Vrije Univ Amsterdam, Amsterdam UMC, Dept Clin Chem, Amsterdam Neurosci,Neurochem Lab & Biobank, Amsterdam, Netherlands
关键词
Retinal vasculature; Alzheimer's disease; Biomarker; Choroidal thickness; OCTA; Fundus photographs; CHOROIDAL THICKNESS; DIURNAL-VARIATION; DEMENTIA; ATROPHY; RISK;
D O I
10.1016/j.dadm.2019.03.006
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: The retina is a potential source of noninvasive vascular biomarkers for Alzheimer's disease (AD). We assessed retinal microvasculature in well-characterized AD cases, taking ophthalmological confounders into account. Methods: We included 48 amyloid-positive AD patients and 38 amyloid-negative cognitively normal control subjects. All participants underwent ophthalmological screening to exclude interfering ocular disease. Using a multimodal approach, we measured retinal vascular parameters, choroidal thickness, macular vascular density, and foveal avascular zone size. Results: We found no disease effects on retinal vascular measures (all beta's, vertical bar 0.15 vertical bar, all P..2), adjusted for confounders. Venular tortuosity was inversely associated with Fazekas score in control subjects (beta -0.56, P < .01), while vessel density in the outer ring of the macula was inversely associated with Fazekas score in AD cases (beta -0.64, P < .01). Discussion: In conclusion, retinal vasculature did not discriminate patients with AD from control subjects, despite evident changes on clinical, neuroimaging, and cerebrospinal fluid biomarkers, challenging the use of retinal vasculature measurements as AD biomarker. (C) 2019 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer's Association.
引用
收藏
页码:383 / 391
页数:9
相关论文
共 50 条
  • [31] Amyloid beta in nasal secretions may be a potential biomarker of Alzheimer’s disease
    Young Hyo Kim
    Sang-Myung Lee
    Sungbo Cho
    Ju-Hee Kang
    Yang-Ki Minn
    Hyelim Park
    Seong Hye Choi
    Scientific Reports, 9
  • [32] Plasma amyloid-β oligomers level is a biomarker for Alzheimer's disease diagnosis
    Zhou, L.
    Chan, K. H.
    Chu, L. W.
    Kwan, J. S. C.
    Song, Y. Q.
    Chen, L. H.
    Ho, P. W. L.
    Cheng, O. Y.
    Ho, J. W. M.
    Lam, K. S. L.
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2012, 423 (04) : 697 - 702
  • [33] Amyloid- as a biomarker for Alzheimer's disease: quantification methods in body fluids
    Galozzi, Sara
    Marcus, Katrin
    Barkovits, Katalin
    EXPERT REVIEW OF PROTEOMICS, 2015, 12 (04) : 343 - 354
  • [34] Amyloid precursor protein in peripheral granulocytes as a potential biomarker for Alzheimer's disease
    Wang, Xiaonan
    Li, Xihai
    Yang, Jie
    Yu, Ming
    Wu, Jinmei
    BANGLADESH JOURNAL OF PHARMACOLOGY, 2016, 11 : S92 - S97
  • [35] Amyloid beta in nasal secretions may be a potential biomarker of Alzheimer's disease
    Kim, Young Hyo
    Lee, Sang-Myung
    Cho, Sungbo
    Kang, Ju-Hee
    Minn, Yang-Ki
    Park, Hyelim
    Choi, Seong Hye
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [36] Evaluating Amyloid-β Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer's Disease
    Holtta, Mikko
    Hansson, Oskar
    Andreasson, Ulf
    Hertze, Joakim
    Minthon, Lennart
    Nagga, Katarina
    Andreasen, Niels
    Zetterberg, Henrik
    Blennow, Kaj
    PLOS ONE, 2013, 8 (06):
  • [37] Amyloid-β as a Blood Biomarker for Alzheimer's Disease: A Review of Recent Literature
    Wang, Xiaoni
    Sun, Yu
    Li, Taoran
    Cai, Yanning
    Han, Ying
    JOURNAL OF ALZHEIMERS DISEASE, 2020, 73 (03) : 819 - 832
  • [38] Plasma metabolomics in early Alzheimer's disease patients diagnosed with amyloid biomarker
    Pena-Bautista, Carmen
    Roca, Marta
    Hervas, David
    Cuevas, Ana
    Lopez-Cuevas, Rogelio
    Vento, Maximo
    Baquero, Miguel
    Garcia-Blanco, Ana
    Chafer-Pericas, Consuelo
    JOURNAL OF PROTEOMICS, 2019, 200 : 144 - 152
  • [39] Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker
    Toledo, Jon B.
    Shaw, Leslie M.
    Trojanowski, John Q.
    ALZHEIMERS RESEARCH & THERAPY, 2013, 5 (02):
  • [40] Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer's disease
    Ferrari-Souza, Joao Pedro
    Ferreira, Pamela C. L.
    Bellaver, Bruna
    Tissot, Cecile
    Wang, Yi-Ting
    Leffa, Douglas T.
    Brum, Wagner S.
    Benedet, Andrea L.
    Ashton, Nicholas J.
    De Bastiani, Marco Antonio
    Rocha, Andreia
    Therriault, Joseph
    Lussier, Firoza Z.
    Chamoun, Mira
    Servaes, Stijn
    Bezgin, Gleb
    Kang, Min Su
    Stevenson, Jenna
    Rahmouni, Nesrine
    Pallen, Vanessa
    Poltronetti, Nina Margherita
    Klunk, William E.
    Tudorascu, Dana L.
    Cohen, Ann D.
    Villemagne, Victor L.
    Gauthier, Serge
    Blennow, Kaj
    Zetterberg, Henrik
    Souza, Diogo O.
    Karikari, Thomas K.
    Zimmer, Eduardo R.
    Rosa-Neto, Pedro
    Pascoal, Tharick A.
    MOLECULAR PSYCHIATRY, 2022, 27 (11) : 4781 - 4789